Status | Study |
NOT_YET_RECRUITING |
Study Name: Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia Condition: Date: 2023-06-08 Interventions: CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist. |
RECRUITING |
Study Name: Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia Condition: Congenital Adrenal Hyperplasia Date: 2023-06-08 Interventions: CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist. |
Recruiting |
Study Name: A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH Condition: Congenital Adrenal Hyperplasia Date: 2016-08-22 Interventions: Drug: Hydrocortisone Modified release hydrocortisone |
Recruiting |
Study Name: A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia Condition: Congenital Adrenal Hyperplasia Date: 2016-06-01 Interventions: Drug: ATR-101 |
Recruiting |
Study Name: Prenatal Dex Study Condition: Congenital Adrenal Hyperplasia Date: 2016-05-25 Interventions: Behavioral: Neuropsychological and cognitive assessment |
Recruiting |
Study Name: Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia Condition: Congenital Adrenal Hyperplasia Date: 2016-02-26 Interventions: Drug: Chronocort® Chronoc |
Recruiting |
Study Name: COrticosteroid in Congenital Adrenal Hyperplasia Condition: Congenital Adrenal Hyperplasia Date: 2015-07-27 Interventions: Biological: Hormonal balance measurements |
Not yet recruiting |
Study Name: Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1 Condition: Congenital Adrenal Hyperplasia Date: 2015-04-24 Interventions: Drug: Abiraterone acetate This is a dose escalation study. Up to 3 successive cohorts of 8 subjects each |
Withdrawn |
Study Name: Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia Condition: Congenital Adrenal Hyperplasia Date: 2015-01-20 Interventions: Drug: NBI-77860 |
Recruiting |
Study Name: Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia Condition: Addison Disease Adrenal Hyperplasia Congenital Date: 2013-11-28 Interventions: Drug: Solu-Cortef administrati |